Literature DB >> 11893792

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.

Hélène C F Côté1, Zabrina L Brumme, Kevin J P Craib, Christopher S Alexander, Brian Wynhoven, Lillian Ting, Hubert Wong, Marianne Harris, P Richard Harrigan, Michael V O'Shaughnessy, Julio S G Montaner.   

Abstract

BACKGROUND: Nucleoside analogues can induce toxic effects on mitochondria by inhibiting the human DNA polymerase gamma. The toxic effects can range from increased serum lactate levels to potentially fatal lactic acidosis. We studied changes in mitochondrial DNA relative to nuclear DNA in the peripheral-blood cells of patients with symptomatic, nucleoside-induced hyperlactatemia.
METHODS: Total DNA was extracted from blood cells. A nuclear gene and a mitochondrial gene were quantified by real-time polymerase chain reaction. Three groups were studied: 24 controls not infected with the human immunodeficiency virus (HIV), 47 HIV-infected asymptomatic patients who had never been treated with antiretroviral drugs, and 8 HIV-infected patients who were receiving antiretroviral drugs and had symptomatic hyperlactatemia. The patients in the last group were studied longitudinally before, during, and after antiretroviral therapy.
RESULTS: Symptomatic hyperlactatemia was associated with marked reductions in the ratios of mitochondrial to nuclear DNA, which, during therapy, averaged 68 percent lower than those of non-HIV-infected controls and 43 percent lower than those of HIV-infected asymptomatic patients never treated with antiretroviral drugs. After the discontinuation of antiretroviral therapy, there was a statistically significant increase in the ratio of mitochondrial to nuclear DNA (P=0.02). In the patients followed longitudinally, the decline in mitochondrial DNA preceded the increase in venous lactate levels.
CONCLUSIONS: Mitochondrial DNA levels are significantly decreased in patients with symptomatic, nucleoside-related hyperlactatemia, an effect that resolves on the discontinuation of therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11893792     DOI: 10.1056/NEJMoa012035

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  117 in total

1.  Hyperlactatemia and human immunodeficiency virus infection: lessons from the era of antiretroviral monotherapy.

Authors:  Patrick Chariot; Nacer Bourokba; Isabelle Monnet; Romain Gherardi
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  Symptomatic hyperlactatemia in an HIV-positive patient: a case report and discussion.

Authors:  Tony Antoniou; Thea Weisdorf; Kevin Gough
Journal:  CMAJ       Date:  2003-01-21       Impact factor: 8.262

3.  HIV and mitochondria: more than just drug toxicity.

Authors:  Todd Hulgan; Mariana Gerschenson
Journal:  J Infect Dis       Date:  2012-04-03       Impact factor: 5.226

4.  Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individuals.

Authors:  Giovanni Schifitto; Lijuan Deng; Tzu-Min Yeh; Scott R Evans; Thomas Ernst; Jianhui Zhong; David Clifford
Journal:  J Neurovirol       Date:  2010-12-23       Impact factor: 2.643

Review 5.  Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.

Authors:  Mark A Boyd; Andrew M Hill
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

6.  Evaluation of mitochondrial toxicity in Marmota himalayana treated with metacavir, a novel 2',3'-dideoxyguanosine prodrug for treatment of hepatitis B Virus.

Authors:  Pinghu Zhang; Luyong Zhang; Zhenzhou Jiang; Yating Xiong; Hongkui Chen; Yuanqing Tao; Maozhi Hu; Zhan Li
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

7.  Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults.

Authors:  Amy Fleischman; Stine Johnsen; David M Systrom; Mirko Hrovat; Christian T Farrar; Walter Frontera; Kathleen Fitch; Bijoy J Thomas; Martin Torriani; Hélène C F Côté; Steven K Grinspoon
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-02-06       Impact factor: 4.310

Review 8.  Antiretroviral treatment interruptions and risk of non-opportunistic diseases.

Authors:  Kenneth A Lichtenstein
Journal:  Curr HIV/AIDS Rep       Date:  2009-05       Impact factor: 5.071

9.  Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.

Authors:  P Tebas; J Zhang; R Hafner; K Tashima; A Shevitz; K Yarasheski; B Berzins; S Owens; J Forand; S Evans; R Murphy
Journal:  J Antimicrob Chemother       Date:  2009-03-19       Impact factor: 5.790

10.  A new link to mitochondrial impairment in tauopathies.

Authors:  Kathrin L Schulz; Anne Eckert; Virginie Rhein; Sören Mai; Winfried Haase; Andreas S Reichert; Marina Jendrach; Walter E Müller; Kristina Leuner
Journal:  Mol Neurobiol       Date:  2012-07-31       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.